PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19080333-2	2008	We have shown that (125)I labeled triple-helix forming oligonucleotide (TFO) against the androgen receptor gene inhibits androgen receptor expression and cell proliferation of LNCaP prostate cancer cells in vitro.	tfo	72-75	androgen receptor	Homo sapiens	89-106	
19080333-2	2008	We have shown that (125)I labeled triple-helix forming oligonucleotide (TFO) against the androgen receptor gene inhibits androgen receptor expression and cell proliferation of LNCaP prostate cancer cells in vitro.	tfo	72-75	androgen receptor	Homo sapiens	121-138	
19080333-12	2008	(125)I-TFO caused greater inhibition of androgen receptor expression and higher AIs in tumor tissue than TFO.	tfo	7-10	androgen receptor	Homo sapiens	40-57	
19080333-15	2008	CONCLUSIONS: The (125)I-TFO can effectively inhibit androgen receptor expression and tumor growth of human prostate cancer xenografts in vivo.	tfo	24-27	androgen receptor	Homo sapiens	52-69	
19080439-1	2008	OBJECTIVE: To investigate the effects of triple-helix forming oligonucleotide (TFO) and antisense oligonucleotide (ASO) on androgen receptor (AR) expression and tumor growth of human prostate cancer xenografts in nude mice.	tfo	79-82	androgen receptor	Homo sapiens	123-140	
19080439-1	2008	OBJECTIVE: To investigate the effects of triple-helix forming oligonucleotide (TFO) and antisense oligonucleotide (ASO) on androgen receptor (AR) expression and tumor growth of human prostate cancer xenografts in nude mice.	tfo	79-82	androgen receptor	Homo sapiens	142-144	
19080439-10	2008	CONCLUSION: TFO shows significantly higher inhibitory effect on AR expression and tumor growth of human prostate cancer xenograft than ASO, and is a promising agent for prostate cancer gene therapy.	tfo	12-15	androgen receptor	Homo sapiens	64-66